Improvements to treatment strategies for patients upper gastrointestinal cancers have produced an increasing population of people who remain free from disease recurrence in the long term. Weight loss and nutritional problems are common among patients who attain long-term remission and cure after surgery for upper gastrointestinal cancers. However, the mechanisms underlying these problems are not well understood. In this study the investigators aim to determine whether reduced food intake after upper gastrointestinal surgery is caused by early satiety related to exaggerated post-prandial gut hormone responses. This is a randomized, double-blind, placebo controlled, crossover study of the effect of 100μg octreotide SC on ad libitum food intake in patients free from complications or recurrence at least one year post-oesophagectomy, gastrectomy or pancreaticoduodenectomy. A comparator group of age, weight and gender matched subjects will be studied concurrently, and caloric intake and subjective symptom scores after administration of octreotide versus placebo among surgical and comparator subjects will be assessed.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
QUADRUPLE
Enrollment
20
Octreotide 100mcg (1mL) single dose, subcutaneously, into the lower abdomen, 50 minutes prior to eating
0.9% saline (1mL) single dose, subcutaneously, into the lower abdomen, 50 minutes prior to eating
Wellcome Trust-Health Research Board Clinical Research Facility, St. James's Hospital
Dublin, Ireland
Gastrosurgical Laboratory, Sahlgrenska Academy, University of Gothenburg
Gothenburg, Sweden
Ad libitum calorie intake
Total kcals consumed
Time frame: 1 hour
Post-prandial satiety gut hormone response
GLP-1, PYY, OXM plasma concentrations
Time frame: 2 hours
Subjective symptom scores
Modified visual analogue scale scores
Time frame: 3 hours
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.